Dr Axel Ullrich wins 2009 Paul Janssen Award
This article was originally published in Scrip
The 2009 Dr Paul Janssen Award, worth $100,000, has been presented to Dr Axel Ullrich for pioneering the development of genomics-based therapeutics, including Genentech/Roche's HER2-targeted Herceptin (trastuzumab), which is used to treat HER2-positive breast cancer, and Pfizer's multi-targeted kinase inhibitor sunitinib malate (Sutent), which is used to treat renal cell carcinoma.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.